Related Experiment Video
Updated: Apr 18, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Mesothelin biology and the evolving landscape of targeted immunotherapy
Remy Boisgard1, Patrick Chames1, Brigitte Kerfelec1
1Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Abstract:
Due to its restricted expression in normal tissues, its frequent overexpression in various aggressive malignancies, and its involvement in several pro-tumorigenic signaling pathways, mesothelin, a glycosylphosphatidylinositol-anchored cell surface protein, has been identified as a promising tumor-associated antigen. This review provides an up-to-date comprehensive overview regarding the role of mesothelin in cancer. It encompasses the protein structural characteristics, expression profiles, glycosylation patterns, shedding mechanisms, prognostic significance, and functional roles. Subsequently, therapeutic strategies targeting mesothelin that have advanced to clinical trial stage are discussed, including vaccine-based approaches, antibody-mediated immunotherapies, and cell therapies. The remaining challenges of mesothelin targeted treatments are highlighted, along with the ongoing options aimed at overcoming these limitations.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
The Tumor Microenvironment
Tumor Immunotherapy

